

1. Moreno-Fuquen R, Hurtado-Angulo M, Arango-Daraviña K et al. Synthesis, crystal structure, Hirshfeld surface analysis, MEP study and molecular docking of N-{3-[(4-methoxyphenyl)carbamoyl]phenyl}-3-nitrobenzamide as a promising inhibitor of hfxa. *Acta Crystallogr E Crystallogr Commun* 2020; 76:1762-1767.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33209349>
2. Duraes AR, de Souza Lima Bitar Y, Schonhofen IS et al. Rivaroxaban Versus Warfarin in Patients with Mechanical Heart Valves: Open-Label, Proof-of-Concept trial-The RIWA study. *Am J Cardiovasc Drugs* 2020.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33150497>
3. Brouwer MA, van Vugt SP, Focks JJ et al. Rivaroxaban Plasma Levels and Levetiracetam. *Ann Intern Med* 2020; 173:770-771.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33137266>
4. Hellfritsch M, Christensen J, Nielsen LP. Rivaroxaban Plasma Levels and Levetiracetam. *Ann Intern Med* 2020; 173:771.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33137273>
5. Paciullo F, Costa C, Gresele P. Rivaroxaban Plasma Levels and Levetiracetam. *Ann Intern Med* 2020; 173:772.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33137271>
6. Punia V. Rivaroxaban Plasma Levels and Levetiracetam. *Ann Intern Med* 2020; 173:771-772.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33137272>
7. Kim J, Jang HJ, Schellingerhout D et al. Short-term Cessation of Dabigatran Causes a Paradoxical Prothrombotic State. *Ann Neurol* 2020.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33219556>
8. Brokmeier H, Kido K. Off-label Use for Direct Oral Anticoagulants: Valvular Atrial Fibrillation, Heart Failure, Left Ventricular Thrombus, Superficial Vein Thrombosis, Pulmonary Hypertension-a Systematic Review. *Ann Pharmacother* 2020;1060028020970618.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33148014>
9. Sezai A, Taoka M, Osaka S et al. A Comparative Prospective Observational Study on the Use of Direct Oral Anticoagulants after Cardiac Surgery for the Management of Atrial Fibrillation. *Ann Thorac Cardiovasc Surg* 2020.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33208579>
10. Matschinske J, Salgado-Albarrán M, Sadegh S et al. Individuating Possibly Repurposable Drugs and Drug Targets for COVID-19 Treatment through Hypothesis-Driven Systems Medicine Using CoVex. *Assay Drug Dev Technol* 2020.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33164550>
11. Dufrost V, Wahl D, Zuily S. Direct oral anticoagulants in antiphospholipid syndrome: Meta-analysis of randomized controlled trials. *Autoimmun Rev* 2020;102711.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33197580>
12. Wang TF, Waller AP, Lin E et al. A pilot randomized trial of atorvastatin as adjunct therapy in patients with acute venous thromboembolism. *Blood Coagul Fibrinolysis* 2020.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33196511>
13. Sakamoto Y, Ishigaki K, Ishikawa C et al. Successful management of portal vein thrombosis in a Yorkshire Terrier with protein-losing enteropathy. *BMC Vet Res* 2020; 16:418.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33138806>
14. Liu A, Fang S, Kapoor K, Babar-Craig H. Haemorrhagic nasal polyp mimicking melanoma in an 83-year-old on rivaroxaban. *BMJ Case Rep* 2020; 13.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33148575>
15. Sudo G, Goto A, Fujisawa T, Nakase H. Haemorrhagic exfoliative oesophagitis associated with nasogastric tube placement. *BMJ Case Rep* 2020; 13.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33229484>
16. Yang Y, Qidwai U, Burton BJL, Canepa C. Bilateral, vertical supranuclear gaze palsy following unilateral midbrain infarct. *BMJ Case Rep* 2020; 13.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33148560>
17. Evans A, Davies M, Osborne V et al. Evaluation of the incidence of bleeding in patients prescribed rivaroxaban for the treatment and prevention of deep vein thrombosis and pulmonary embolism in UK secondary care: an observational cohort study. *BMJ Open* 2020; 10:e038102.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33148732>
18. Ji Q, Zhang C, Xu Q et al. The impact of ABCB1 and CES1 polymorphisms on dabigatran pharmacokinetics

- and pharmacodynamics in patients with atrial fibrillation. *Br J Clin Pharmacol* 2020.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33179295>
19. Liu Z, Xie Q, Xiang Q et al. Anti-FXa-IIa activity test in Asian and its potential role for drug adherence evaluation in patients with direct oral anticoagulants: a nationwide multi-center synchronization study. *Cardiovasc Diagn Ther* 2020; 10:1293-1302.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33224753>
 20. Xiong Y, Zhou W, Li M et al. Association between platelet count and the risk of bleeding among patients with nonvalvular atrial fibrillation taking dabigatran after radiofrequency ablation: a cohort study. *Cardiovasc Diagn Ther* 2020; 10:1175-1183.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33224741>
 21. Sun X, Ze B, Zhang LJ et al. Hemorrhage Risk Profiles among Different Antithrombotic Regimens: Evidence from a Real-World Analysis of Postmarketing Surveillance Data. *Cardiovasc Drugs Ther* 2020.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33226545>
 22. Vilain K, Li H, Kwong WJ et al. Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 Trial. *Circ Cardiovasc Qual Outcomes* 2020; 13:e006511.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33148013>
 23. Toyoda K, Uchiyama S, Hagihara Y et al. Dabigatran vs. Aspirin for Secondary Prevention After Embolic Stroke of Undetermined Source – Japanese Subanalysis of the RE-SPECT ESUS Randomized Controlled Trial. *Circ J* 2020.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=3313228>
 24. Hiatt WR, Bonaca MP, Patel MR et al. Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety. *Circulation* 2020.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33138628>
 25. Kaul S, Stockbridge N, Butler J. Benefit-Risk Tradeoffs in Assessment of New Drugs and Devices. *Circulation* 2020; 142:1974-1988.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33196311>
 26. Xie C, Hang Y, Zhu J et al. Benefit and risk of adding rivaroxaban in patients with coronary artery disease: A systematic review and meta-analysis. *Clin Cardiol* 2020.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33219708>
 27. Tapaskar N, Ham SA, Micic D, Sengupta N. Restarting Warfarin versus Direct Oral Anticoagulants after Major Gastrointestinal Bleeding and Associated Outcomes in Atrial Fibrillation: A Cohort Study. *Clin Gastroenterol Hepatol* 2020.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33227458>
 28. Harano T, Rivossecchi RM, Morrell MR, Sanchez PG. Dabigatran reversal with idarucizumab prior to lung transplantation. *Clin Transplant* 2020:e14142.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33150658>
 29. Lange NW, Lee JH, Liu EC et al. Deceased donor renal transplantation in patients on apixaban at time of transplant surgery: A case series. *Clin Transplant* 2020:e14148.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33222253>
 30. Wong EKC, Belza C, Naimark DMJ et al. Cost-effectiveness of antithrombotic agents for atrial fibrillation in older adults at risk for falls: a mathematical modelling study. *CMAJ Open* 2020; 8:E706-e714.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33158928>
 31. Reçber T, Haznedaroğlu İ C, Çelebier M. Review on Characteristics and Analytical Methods of Rivaroxaban. *Crit Rev Anal Chem* 2020:1-13.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33146024>
 32. Jurin I, Lucijanić M, Šakić Z et al. Patterns of anticoagulation therapy in atrial fibrillation: results from a large real-life single-center registry. *Croat Med J* 2020; 61:440-449.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33150762>
 33. Isaq NA, Vinson WM, Rahnama-Moghadam S. Apixaban-induced cutaneous hypersensitivity: a case series with evidence of cross-reactivity. *Dermatol Online J* 2020; 26.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33147679>
 34. Huang HK, Liu PP, Lin SM et al. Risk of developing diabetes in patients with atrial fibrillation taking non-vitamin K antagonist oral anticoagulants or warfarin: A nationwide cohort study. *Diabetes Obes Metab* 2020.

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33140538>
35. Dabigatran. In: Drugs and Lactation Database (LactMed). Bethesda (MD): National Library of Medicine (US); 2006.
 36. Rivaroxaban. In: Drugs and Lactation Database (LactMed). Bethesda (MD): National Library of Medicine (US); 2006.
 37. Apixaban. In: Drugs and Lactation Database (LactMed). Bethesda (MD): National Library of Medicine (US); 2006.
 38. Ogiyama H, Inoue T, Maekawa A et al. Effect of anticoagulants on the risk of delayed bleeding after colorectal endoscopic submucosal dissection. *Endosc Int Open* 2020; 8:E1654-e1663.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33140021>
 39. Khorana AA, Cohen AT, Carrier M et al. Prevention of venous thromboembolism in ambulatory patients with cancer. *ESMO Open* 2020; 5.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33229505>
 40. De Luca L, Valgimigli M. Unravelling the puzzle of antithrombotic therapies for complex percutaneous coronary intervention. *Eur Heart J Cardiovasc Pharmacother* 2020.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33175148>
 41. Nair RM, Maroo A. The concoction of cancer, catheter, and intracardiac clot: a case report describing a potential treatment strategy. *Eur Heart J Case Rep* 2020; 4:1-6.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33204995>
 42. Kauppila M, Backman JT, Niemi M, Lapatto-Reiniluoto O. Incidence, preventability, and causality of adverse drug reactions at a university hospital emergency department. *Eur J Clin Pharmacol* 2020.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33188450>
 43. Cappato R, Chiarito M, Giustozzi M et al. Lower dose direct oral anticoagulants and improved survival: A combined analysis in patients with established atherosclerosis. *Eur J Intern Med* 2020.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33158720>
 44. Kapourani A, Eleftheriadou K, Kontogiannopoulos KN, Barmapalexis P. Evaluation of rivaroxaban amorphous solid dispersions physical stability via molecular mobility studies and molecular simulations. *Eur J Pharm Sci* 2020:105642.
 45. Zeymer U, Leiva O, Hohnloser SH et al. Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST elevation myocardial infarction: results from the randomised RE-DUAL PCI trial. *EuroIntervention* 2020.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33164896>
 46. Jones K, Pham C, Aguilar C, Sheth S. Retrospective Review on the Safety and Efficacy of Direct Oral Anticoagulants Compared With Warfarin in Patients With Cirrhosis. *Fed Pract* 2020; 37:479-485.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33132687>
 47. Shen NN, Wu Y, Wang N et al. Direct Oral Anticoagulants vs. Vitamin-K Antagonists in the Elderly With Atrial Fibrillation: A Systematic Review Comparing Benefits and Harms Between Observational Studies and Randomized Controlled Trials. *Front Cardiovasc Med* 2020; 7:132.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33134323>
 48. Saib S, Hodin S, He Z et al. Is the human model RPTEC/TERT1 a relevant model for assessing renal drug efflux? *Fundam Clin Pharmacol* 2020.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33185296>
 49. Di Cesare M, Jarvis JD, Scarlatescu O et al. NOACs Added to WHO's Essential Medicines List: Recommendations for Future Policy Actions. *Glob Heart* 2020; 15:67.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33150132>
 50. Li X, Yang J, Xu D. Anticoagulation in Patients with Heart Failure and Sinus Rhythm. *Int Heart J* 2020.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33191346>
 51. Dubner S, Saraiva JFK, Fragoso JCN et al. Effectiveness and safety of dabigatran in Latin American patients with atrial fibrillation: Two years follow up results from GLORIA-AF registry. *Int J Cardiol Heart Vasc* 2020; 31:100666.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33195793>
 52. Jou-Valencia D, Dijkstra FA. Case report of simultaneous presentation of pulmonary embolism and pericardial effusion following an oncological esophagectomy. *Int J Surg Case Rep* 2020; 77:252-255.

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33189005>
53. Kitano D, Migita S, Li Y et al. Effect of Rivaroxaban and Clopidogrel Combination Therapy on In-Stent Responses After Everolimus-Eluting Stent Implantation in a Porcine Coronary Model. *J Atheroscler Thromb* 2020.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33208566>
 54. Apostel H, Winckers K, Bidar E, Schreiber JU. Successful Antithrombin Administration in Andexanet Alfa-Associated Heparin Resistance. *J Cardiothorac Vasc Anesth* 2020.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33187852>
 55. D'Amario D, Galli M, Canonico F et al. ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrial fibrillation: the (ORIGAMI) study. *J Cardiovasc Med (Hagerstown)* 2020.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33186237>
 56. Marchetti G, Bernardini F, Romoli M, Urbinati S. Switching across direct oral anticoagulants: a real-life-setting pilot prospective study. *J Cardiovasc Med (Hagerstown)* 2020.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33186238>
 57. Lee ZX, Ang E, Lim XT, Arain SJ. Association of Risk of Dementia with Direct Oral Anticoagulants versus Warfarin use in Patients with Non-valvular Atrial Fibrillation: A Systematic Review and Meta-analysis. *J Cardiovasc Pharmacol* 2020.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33136766>
 58. Gorczyca I, Jelonek O, Uziębło-Życzkowska B et al. Trends in the Prescription of Non-Vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation: Results of the Polish Atrial Fibrillation (POL-AF) Registry. *J Clin Med* 2020; 9.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33167503>
 59. Liu L, Hong D, Ma K, Lu X. Cost-effectiveness of rivaroxaban versus warfarin in non-valvular atrial fibrillation patients with chronic kidney disease in China. *J Clin Pharm Ther* 2020.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33226144>
 60. Willmann S, Coboeken K, Kapsa S et al. Applications of Physiologically-Based Pharmacokinetic Modeling of Rivaroxaban - Renal and Hepatic Impairment and Drug-Drug Interaction Potential. *J Clin Pharmacol* 2020.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33205449>
 61. Motta JP, Palese S, Giorgio C et al. Increased mucosal thrombin is associated with Crohn's disease and causes inflammatory damage through Protease-Activated Receptors activation. *J Crohns Colitis* 2020.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33201214>
 62. Zabczyk M, Natorka J, Bagoly Z et al. Plasma fibrin clots of pulmonary embolism patients present increased amounts of factor XIII and alpha2-antiplasmin at 3 months' anticoagulation since the acute phase. *J Physiol Pharmacol* 2020; 71.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33214340>
 63. Saito K, Ishii K, Furuta K et al. Recurrent Cerebral Venous Thrombosis Treated with Direct Oral Anticoagulants in a Japanese Man with Hereditary Protein C Deficiency. *J Stroke Cerebrovasc Dis* 2020;105320.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33131982>
 64. Kampouraki E, Abohelaika S, Avery P et al. Elderly people are inherently sensitive to the pharmacological activity of rivaroxaban: implications for DOAC prescribing. *J Thromb Thrombolysis* 2020.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33131001>
 65. Rossier C, Spoutz P, Schaefer M et al. Working smarter, not harder: evaluating a population health approach to anticoagulation therapy management. *J Thromb Thrombolysis* 2020.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33222115>
 66. Wallvik N, Renlund H, Sjölander A. Bleeding risk in patients with venous thromboembolic events treated with new oral anticoagulants. *J Thromb Thrombolysis* 2020.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33140837>
 67. Chopard R, Albertsen IE, Piazza G. Diagnosis and Treatment of Lower Extremity Venous Thromboembolism: A Review. *Jama* 2020; 324:1765-1776.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33141212>
 68. Gorbatenko VS, Gerasimenko AS, Shatalova OV. [Comparative efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease]. *Kardiologiya* 2020; 60:102-109.

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33131481>
69. Obrezan AG, Kulikov NV. [Atrial Fibrillation and Diabetes Mellitus: the Control of Thromboembolic Risk]. *Kardiologiya* 2020; 60:108-114.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33155949>
70. Yavelov IS. [Direct Oral Anticoagulant Edoxaban in Patients with Non-Valvular Atrial Fibrillation: Results of Direct Comparison with Warfarin]. *Kardiologiya* 2020; 60:124-129.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33155968>
71. Isaacs DJ, Johnson EJ, Hofmann ER et al. Primary care physicians comprehensively manage acute pulmonary embolism without higher-level-of-care transfer: A report of two cases. *Medicine (Baltimore)* 2020; 99:e23031.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33157953>
72. Moutzi D, Kakoura M. Pulmonary embolism in Behcet's disease: a case report. *Monaldi Arch Chest Dis* 2020; 90.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33161693>
73. Bonaca MP, Bauersachs RM, Hiatt WR. Rivaroxaban in Peripheral Artery Disease after Revascularization. Reply. *N Engl J Med* 2020; 383:2090-2091.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33207109>
74. Gremmel T. Rivaroxaban in Peripheral Artery Disease after Revascularization. *N Engl J Med* 2020; 383:2090.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33207108>
75. Guimarães HP, Lopes RD, de Barros ESPGM et al. Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. *N Engl J Med* 2020.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33196155>
76. Ultee KHJ, Steunenberg SL, Schouten O. Rivaroxaban in Peripheral Artery Disease after Revascularization. *N Engl J Med* 2020; 383:2089-2090.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33207107>
77. Yamazaki T, Hosaka R, Torii Y et al. [Monotherapy using a direct oral anticoagulant (apixaban) for catheter thrombosis and pulmonary thromboembolism in a patient with ulcerative colitis: a case report]. *Nihon Shokakibyo Gakkai Zasshi* 2020; 117:992-1000.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33177262>
78. Choi EK, Lee YS, Chern AKC et al. Real-world evaluation of perception, convenience and anticoagulant treatment satisfaction of patients with atrial fibrillation switched from long-term vitamin K antagonist treatment to dabigatran. *Open Heart* 2020; 7.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33184127>
79. Ngo LT, Yang SY, Tran QT et al. Effects of Carbamazepine and Phenytoin on Pharmacokinetics and Pharmacodynamics of Rivaroxaban. *Pharmaceutics* 2020; 12.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33143037>
80. Segec A, Slattery J, Morales DR et al. Does additional monitoring status increase the reporting of ADRs? An interrupted time series analysis of EudraVigilance data. *Pharmacoepidemiol Drug Saf* 2020.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33197106>
81. Bixby AL, Lichvar AB, Salerno D, Park JM. Use of Direct-acting Oral Anticoagulants in Solid Organ Transplantation: A Systematic Review. *Pharmacotherapy* 2020.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33155327>
82. Vidal Vílchez B, Roa Colomo A, Martín-Lagos Maldonado A. GASTROPARESIS SECONDARY TO PULMONARY VEIN CRYOABLATION: A FACTOR TO CONSIDER. *Rev Esp Enferm Dig* 2020.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33222475>
83. Allain JS, Paven E, Henriot B et al. [Libman-Sacks endocarditis under apixaban in a patient with a high-risk profile venous antiphospholipid syndrome]. *Rev Med Interne* 2020.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33153775>
84. Monteiro P. Edoxaban Treatment in routine clinical practice in patients with non-valvular Atrial Fibrillation (ETNA-AF) in Iberia: Baseline data. *Rev Port Cardiol* 2020; 39:651-662.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33190965>
85. Haider A, Abdul Razzaque MR, Yaqub S. Spontaneous Renal Artery Dissection with Bilateral Renal Infarction Successfully Treated with Rivaroxaban. *Saudi J Kidney Dis Transpl* 2020; 31:1110-1116.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33229777>
86. Mastenbroek TG, Karel MFA, Nagy M et al. Vascular protective effect of aspirin and rivaroxaban upon

- endothelial denudation of the mouse carotid artery. *Sci Rep* 2020; 10:19360.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33168914>
87. Panizzi P, Krohn-Grimberghe M, Keliher E et al. Multimodal imaging of bacterial-host interface in mice and piglets with *Staphylococcus aureus* endocarditis. *Sci Transl Med* 2020; 12.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33148623>
88. Ding WY, Lip GYH, Fairbairn T et al. Short-Term Apixaban for Documented Left Atrial Appendage Thrombus in High-Risk Atrial Fibrillation Patients Undergoing Left Atrial Appendage Occlusion. *TH Open* 2020; 4:e351-e353.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33145476>
89. Ageno W, Vedovati MC, Cohen A et al. Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. *Thromb Haemost* 2020.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33202447>
90. Billett HH, Reyes-Gil M, Szymanski J et al. Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality. *Thromb Haemost* 2020.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33186991>
91. Cohen A, Keshishian A, Lee T et al. Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data Analysis. *Thromb Haemost* 2020.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33171521>
92. Haastrup SB, Hellfritsch M, Nybo M et al. Real-world experience with reversal of dabigatran by idarucizumab. *Thromb Res* 2020; 197:179-184.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33227654>
93. Khan AA, Hardy LJ, Shantsila E et al. Observations on clot properties in atrial fibrillation: Relation to renal function and choice of anticoagulant. *Thromb Res* 2020; 197:69-76.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33189061>
94. Knoll W, Mallick R, Wells PS, Carrier M. Safety and efficacy of apixaban thromboprophylaxis in cancer patients with metastatic disease: A post-hoc analysis of the AVERT trial. *Thromb Res* 2020; 197:13-15.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33160115>
95. Mainbourg S, Cucherat M, Provencher S et al. Twice- or Once-Daily Dosing of Direct Oral Anticoagulants, a systematic review and meta-analysis. *Thromb Res* 2020; 197:24-32.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33161284>
96. Samuelson Bannow BT, Chi V, Sochacki P et al. Heavy menstrual bleeding in women on oral anticoagulants. *Thromb Res* 2020; 197:114-119.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33212377>
97. Speed V, Patel JP, Roberts LN et al. UK real-world experience of prescribing rivaroxaban for acute venous thromboembolism in obesity: Results from the FIRST Registry. *Thromb Res* 2020; 197:16-19.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33160116>
98. Morais QCD, Santos MS. Multi-Criteria Model for Evaluating Drugs to Prevent Deep Venous Thrombosis Associated With Orthopedic Surgery: A Hospital-Based Case Study. *Value Health Reg Issues* 2020; 23:105-111.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33171358>
99. Ding Y, Li X, Zhou M et al. Factor Xa inhibitor rivaroxaban suppresses experimental abdominal aortic aneurysm progression via attenuating aortic inflammation. *Vascul Pharmacol* 2020:106818.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33227452>
100. Mokadem ME, Hassan A, Algaby AZ. Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. *Vascular* 2020:1708538120971148.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33153401>
101. Ali F, Matharu T, Nagesh RV et al. Calciphylaxis in Stage 3 Chronic Kidney Disease on Apixaban Successfully Treated With Sodium Thiosulfate: A Case Report. *Wounds* 2020; 32:E42-e49.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33166270>